Neuroscience Division, Garvan Institute of Medical Research, St Vincent's Hospital, Sydney, NSW, Australia.
Diabetes and Metabolism Division, Garvan Institute of Medical Research, St Vincent's Hospital, Sydney, NSW, Australia.
Nat Commun. 2021 May 11;12(1):2622. doi: 10.1038/s41467-021-22925-3.
Obesity is caused by an imbalance between food intake and energy expenditure (EE). Here we identify a conserved pathway that links signalling through peripheral Y1 receptors (Y1R) to the control of EE. Selective antagonism of peripheral Y1R, via the non-brain penetrable antagonist BIBO3304, leads to a significant reduction in body weight gain due to enhanced EE thereby reducing fat mass. Specifically thermogenesis in brown adipose tissue (BAT) due to elevated UCP1 is enhanced accompanied by extensive browning of white adipose tissue both in mice and humans. Importantly, selective ablation of Y1R from adipocytes protects against diet-induced obesity. Furthermore, peripheral specific Y1R antagonism also improves glucose homeostasis mainly driven by dynamic changes in Akt activity in BAT. Together, these data suggest that selective peripheral only Y1R antagonism via BIBO3304, or a functional analogue, could be developed as a safer and more effective treatment option to mitigate diet-induced obesity.
肥胖是由食物摄入和能量消耗(EE)之间的失衡引起的。在这里,我们确定了一条保守的途径,将通过外周 Y1 受体(Y1R)的信号传递与 EE 的控制联系起来。通过非穿透性脑的选择性外周 Y1R 拮抗剂 BIBO3304 进行选择性拮抗,可通过增强 EE 导致体重明显增加,从而减少脂肪量。具体而言,棕色脂肪组织(BAT)的产热因 UCP1 升高而增强,同时伴随着白色脂肪组织的广泛褐变,无论是在小鼠还是人类中。重要的是,从脂肪细胞中选择性剔除 Y1R 可预防饮食引起的肥胖。此外,外周特异性 Y1R 拮抗作用也可改善葡萄糖稳态,主要由 BAT 中 Akt 活性的动态变化驱动。总之,这些数据表明,通过 BIBO3304 或功能类似物进行选择性外周 Y1R 拮抗作用,可能被开发为一种更安全、更有效的治疗选择,以减轻饮食引起的肥胖。